Skip to main content
Erschienen in: Endocrine 2/2011

01.04.2011 | Original Article

Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population

verfasst von: Jaeseong Jo, Ji Eun Yun, Heeyeon Lee, Heejin Kimm, Sun Ha Jee

Erschienen in: Endocrine | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Total bilirubin, not direct or indirect bilirubin, has been reported to associate inversely with metabolic syndrome. Therefore, we aimed to evaluate the association between bilirubin subtypes and metabolic syndrome among the Korean population. This study included 5,231 Koreans (3,008 men, 2,223 women) aged 30–87 years, who visited the Health promotion centers in Seoul from April, 2006 to June, 2007. The associations of direct, indirect, and total bilirubin classified in quartiles with metabolic syndrome were measured by logistic regression analyses in men and women. Odds ratios (95% confidence intervals) of the lowest, 2nd and 3rd quartiles of direct serum bilirubin compared with the highest quartile (reference) were 2.3 (1.6–3.2), 1.8 (1.3–2.4), and 1.8 (1.4–2.4) among men, and 5.5 (2.6–11.5), 3.1 (1.5–6.7), and 1.9 (0.9–4.3) among women, respectively. In a multivariable adjusted model, however, the significance of inverse associations with total and indirect bilirubin became attenuated. The relation was consistent particularly with direct bilirubin in subgroups of metabolic syndrome components such as central obesity, hypertriglyceridemia, hyperglycemia, and low HDL-cholesterol in both men and women. Of the three subtypes of serum bilirubin, the inverse association of metabolic syndrome was significantly apparent and consistent with direct bilirubin.
Literatur
1.
Zurück zum Zitat R. Stocker, Y. Yamamoto, A.F. McDonagh, A.N. Glazer, B.N. Ames, Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043–1046 (1987)PubMedCrossRef R. Stocker, Y. Yamamoto, A.F. McDonagh, A.N. Glazer, B.N. Ames, Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043–1046 (1987)PubMedCrossRef
2.
Zurück zum Zitat T.W. Wu, J. Wu, R.K. Li, D. Mickle, D. Carey, Albumin-bound bilirubins protect hyman ventricular myocytes against oxyradical damage. Biochem. Cell Biol. 69, 683–688 (1991)PubMedCrossRef T.W. Wu, J. Wu, R.K. Li, D. Mickle, D. Carey, Albumin-bound bilirubins protect hyman ventricular myocytes against oxyradical damage. Biochem. Cell Biol. 69, 683–688 (1991)PubMedCrossRef
3.
Zurück zum Zitat H.A. Schwertner, L. Vitek, Gilbert syndrome, UGT1A1*28 allel, and cardiovascular disease risk: Possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 198, 1–11 (2008)PubMedCrossRef H.A. Schwertner, L. Vitek, Gilbert syndrome, UGT1A1*28 allel, and cardiovascular disease risk: Possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 198, 1–11 (2008)PubMedCrossRef
4.
Zurück zum Zitat S.C. Hunt, F. Kronenberg, J.H. Eckfeldt, P.N. Hopkins, R.H. Myers, G. Heiss, Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis 154, 747–754 (2001)PubMedCrossRef S.C. Hunt, F. Kronenberg, J.H. Eckfeldt, P.N. Hopkins, R.H. Myers, G. Heiss, Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis 154, 747–754 (2001)PubMedCrossRef
5.
Zurück zum Zitat B. Krijgsman, J.A. Papadkis, E.S. Ganotakis, D.P. Mikhailidis, G. Hamilton, The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int. Angiol. 21, 44–52 (2002)PubMed B. Krijgsman, J.A. Papadkis, E.S. Ganotakis, D.P. Mikhailidis, G. Hamilton, The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int. Angiol. 21, 44–52 (2002)PubMed
6.
Zurück zum Zitat D. Erdogan, H. Gullu, E. Yildirim, D. Tok, O. Ciftci, S.T. Baycan, H. Muderrisoglu, Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 184, 431–437 (2006)PubMedCrossRef D. Erdogan, H. Gullu, E. Yildirim, D. Tok, O. Ciftci, S.T. Baycan, H. Muderrisoglu, Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 184, 431–437 (2006)PubMedCrossRef
7.
Zurück zum Zitat H.J. Kimm, J.E. Yun, J. Jo, S.H. Jee, Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 40, 3422–3427 (2009)PubMedCrossRef H.J. Kimm, J.E. Yun, J. Jo, S.H. Jee, Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 40, 3422–3427 (2009)PubMedCrossRef
8.
Zurück zum Zitat E.S. Ford, A.H. Mokdad, W.H. Giles, D.W. Brown, The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 52, 2346–2352 (2003)PubMedCrossRef E.S. Ford, A.H. Mokdad, W.H. Giles, D.W. Brown, The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 52, 2346–2352 (2003)PubMedCrossRef
9.
Zurück zum Zitat P.M. Gorter, J.K. Olijhoek, Y. van der Graaf, A. Algra, T.J. Rabelink, F.L. Visseren, Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 173, 363–369 (2004)PubMedCrossRef P.M. Gorter, J.K. Olijhoek, Y. van der Graaf, A. Algra, T.J. Rabelink, F.L. Visseren, Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 173, 363–369 (2004)PubMedCrossRef
10.
Zurück zum Zitat M.K. Rutter, J.B. Meigs, L.M. Sullivan, R.B. D’Agostino, P.W. Wilson, C-reactive protein, the metabolic syndrome and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110, 380–385 (2004)PubMedCrossRef M.K. Rutter, J.B. Meigs, L.M. Sullivan, R.B. D’Agostino, P.W. Wilson, C-reactive protein, the metabolic syndrome and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110, 380–385 (2004)PubMedCrossRef
11.
Zurück zum Zitat J.S. Torgerson, A.K. Lindroos, C.D. Sjostrom, R. Olsson, L. Lissner, L. Sjostrom, Are elevated aminotransferases and decreased bilirubin additional characteristics of the metabolic syndrome? Obes. Res. 5, 105–114 (1997)PubMed J.S. Torgerson, A.K. Lindroos, C.D. Sjostrom, R. Olsson, L. Lissner, L. Sjostrom, Are elevated aminotransferases and decreased bilirubin additional characteristics of the metabolic syndrome? Obes. Res. 5, 105–114 (1997)PubMed
12.
Zurück zum Zitat L.Y. Lin, H.K. Kuo, J.J. Hwang, L.P. Lai, F.T. Chiang, C.D. Tseng, J.L. Lin, Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 203, 563–568 (2009)PubMedCrossRef L.Y. Lin, H.K. Kuo, J.J. Hwang, L.P. Lai, F.T. Chiang, C.D. Tseng, J.L. Lin, Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 203, 563–568 (2009)PubMedCrossRef
13.
Zurück zum Zitat L.H. Bremier, K.A. Spyropolous, A.F. Winder, D.P. Mikhailidis, G. Hamilton, Is bilirubin protective against coronary artery disease? Clin. Chem. 40, 1987–1988 (1994) L.H. Bremier, K.A. Spyropolous, A.F. Winder, D.P. Mikhailidis, G. Hamilton, Is bilirubin protective against coronary artery disease? Clin. Chem. 40, 1987–1988 (1994)
14.
Zurück zum Zitat L.H. Bremier, G. Wannamethee, S. Ebrahim, A.G. Shaper, Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin. Chem. 41, 1504–1508 (1995) L.H. Bremier, G. Wannamethee, S. Ebrahim, A.G. Shaper, Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin. Chem. 41, 1504–1508 (1995)
15.
Zurück zum Zitat H.A. Schwertner, W.G. Jackson, G. Tolan, Association of Low serum concentration of bilirubin with increased risk of coronary artery disease. Clin. Chem. 40, 18–23 (1994)PubMed H.A. Schwertner, W.G. Jackson, G. Tolan, Association of Low serum concentration of bilirubin with increased risk of coronary artery disease. Clin. Chem. 40, 18–23 (1994)PubMed
16.
Zurück zum Zitat S. Pineda, O.Y. Bang, J.L. Saver, S. Starkman, S.W. Yun, D.S. Liebeskind, L.K. Ali, S.H. Shah, B. Ovbiagele, Association of serum bilirubin with ischemic stroke outcomes. J. Stroke Cerebrovasc. Dis. 17, 147–152 (2008)PubMedCrossRef S. Pineda, O.Y. Bang, J.L. Saver, S. Starkman, S.W. Yun, D.S. Liebeskind, L.K. Ali, S.H. Shah, B. Ovbiagele, Association of serum bilirubin with ischemic stroke outcomes. J. Stroke Cerebrovasc. Dis. 17, 147–152 (2008)PubMedCrossRef
17.
Zurück zum Zitat H.J. Hwang, S.H. Kim, Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults. Clin. Chim. Acta 411, 1496–1501 (2010)PubMedCrossRef H.J. Hwang, S.H. Kim, Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults. Clin. Chim. Acta 411, 1496–1501 (2010)PubMedCrossRef
18.
Zurück zum Zitat T. Nakagami, K. Toyomura, T. Kinoshita, S. Morisawa, A beneficial role of bile pigments as an endogenous tissue protector: anticomplement effects of biliverdin and conjugated bilirubin. Biochim. Biophys. Acta 1158, 189–193 (1993)PubMed T. Nakagami, K. Toyomura, T. Kinoshita, S. Morisawa, A beneficial role of bile pigments as an endogenous tissue protector: anticomplement effects of biliverdin and conjugated bilirubin. Biochim. Biophys. Acta 1158, 189–193 (1993)PubMed
19.
Zurück zum Zitat M. Mamtani, A. Patel, R. Renge, H. Kulkarni, Prognostic value of direct bilirubin in neonatal hyperbilirubinemia. Indian J. Pediatr. 74, 819–822 (2007)PubMedCrossRef M. Mamtani, A. Patel, R. Renge, H. Kulkarni, Prognostic value of direct bilirubin in neonatal hyperbilirubinemia. Indian J. Pediatr. 74, 819–822 (2007)PubMedCrossRef
20.
Zurück zum Zitat S. Shiomi, D. Habu, T. Kuroki, S. Ishida, N. Tatsumi, Clinical usefulness of conjugated bilirubin levels in patients with acute liver diseases. J. Gastroenterol. 34, 88–93 (1993)CrossRef S. Shiomi, D. Habu, T. Kuroki, S. Ishida, N. Tatsumi, Clinical usefulness of conjugated bilirubin levels in patients with acute liver diseases. J. Gastroenterol. 34, 88–93 (1993)CrossRef
21.
Zurück zum Zitat B. Li, Z. Wang, J.J. Fang, C.Y. Xu, W.X. Chen, Evaluation of prognostic markers in severe drug-induced liver disease. World J. Gastroenterol. 13, 628–632 (2007)PubMed B. Li, Z. Wang, J.J. Fang, C.Y. Xu, W.X. Chen, Evaluation of prognostic markers in severe drug-induced liver disease. World J. Gastroenterol. 13, 628–632 (2007)PubMed
22.
Zurück zum Zitat O. Yavuz, S. Aras, Interaction between serum bilirubin level and lipid profile. T Klin. Tip Bilim. 22, 276–280 (2002) O. Yavuz, S. Aras, Interaction between serum bilirubin level and lipid profile. T Klin. Tip Bilim. 22, 276–280 (2002)
23.
Zurück zum Zitat R.J. Simon Maxwell, Y.H. Gregory, Free radicals and antioxidants in cardiovascular disease. Br. J. Clin. Pharmacol. 44, 307–317 (1997)CrossRef R.J. Simon Maxwell, Y.H. Gregory, Free radicals and antioxidants in cardiovascular disease. Br. J. Clin. Pharmacol. 44, 307–317 (1997)CrossRef
24.
Zurück zum Zitat T.W. Wu, K.P. Fung, C.C. Yang, Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci. 54, 477–481 (1994) T.W. Wu, K.P. Fung, C.C. Yang, Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci. 54, 477–481 (1994)
25.
Zurück zum Zitat J. Neuzil, R. Stocker, Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J. Biol. Chem. 269, 16712–16719 (1994)PubMed J. Neuzil, R. Stocker, Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J. Biol. Chem. 269, 16712–16719 (1994)PubMed
26.
Zurück zum Zitat T. Yamaguchi, F. Horio, T. Hashizume, M. Ttanaka, S. Ikeda, A. Kakinuma, H. Nakajima, Bilirubin is oxidized in rats treated with endotoxin and acts as a physiological antioxidant synergistically with ascorbic acid in vivo. Biochem. Biophys. Res. Commun. 4, 11–19 (1995)CrossRef T. Yamaguchi, F. Horio, T. Hashizume, M. Ttanaka, S. Ikeda, A. Kakinuma, H. Nakajima, Bilirubin is oxidized in rats treated with endotoxin and acts as a physiological antioxidant synergistically with ascorbic acid in vivo. Biochem. Biophys. Res. Commun. 4, 11–19 (1995)CrossRef
27.
Zurück zum Zitat T. Aizawa, N. Ishizaka, J. Taguchi, S. Kimura, K. Kurokawa, M. Ohno, Baloon injury does not induce heme oxygenase-1 expression, but administration of hemin inhibits neointimal formation in balloon-injury rat carotid artery. Biochem. Biophys. Res. Commun. 261, 302–307 (1999)PubMedCrossRef T. Aizawa, N. Ishizaka, J. Taguchi, S. Kimura, K. Kurokawa, M. Ohno, Baloon injury does not induce heme oxygenase-1 expression, but administration of hemin inhibits neointimal formation in balloon-injury rat carotid artery. Biochem. Biophys. Res. Commun. 261, 302–307 (1999)PubMedCrossRef
28.
Zurück zum Zitat B. Frei, R. Stocker, B.N. Ames, Antioxidant defenses and lipid peroxidation in human blood plasma. Proc. Natl. Acad. Sci. USA 85, 9748–9752 (1988)PubMedCrossRef B. Frei, R. Stocker, B.N. Ames, Antioxidant defenses and lipid peroxidation in human blood plasma. Proc. Natl. Acad. Sci. USA 85, 9748–9752 (1988)PubMedCrossRef
29.
Zurück zum Zitat C. Hammerman, R. Goldstein, M. Kaplan, M. Eran, D. Goldschmidt, A.I. Eidelman, L.M. Gartner, Bilirubin in the premature: toxic waste or natural defense? Clin. Chem. 44, 2551–2553 (1998)PubMed C. Hammerman, R. Goldstein, M. Kaplan, M. Eran, D. Goldschmidt, A.I. Eidelman, L.M. Gartner, Bilirubin in the premature: toxic waste or natural defense? Clin. Chem. 44, 2551–2553 (1998)PubMed
30.
Zurück zum Zitat F. Armutcu, M. Ataymen, H. Atmaca, A. Gurel, Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome. Clin. Chem. Lab. Med. 46, 785–790 (2008)PubMedCrossRef F. Armutcu, M. Ataymen, H. Atmaca, A. Gurel, Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome. Clin. Chem. Lab. Med. 46, 785–790 (2008)PubMedCrossRef
31.
Zurück zum Zitat B. Burchell, R. Hume, Molecular genetic basis of Gilbert’s syndrome. J. Gastroenterol. Hepatol. 14, 960–966 (1999)PubMedCrossRef B. Burchell, R. Hume, Molecular genetic basis of Gilbert’s syndrome. J. Gastroenterol. Hepatol. 14, 960–966 (1999)PubMedCrossRef
32.
Zurück zum Zitat S.J. Yoon, H.S. Lee, S.W. Lee, J.E. Yun, S.Y. Kim, E.R. Cho, S.J. Lee, E.J. Jee, H.Y. Lee, J. Park, H.S. Kim, S.H. Jee, The association between adiponectin and diabetes in the Korean population. Metabolism 57, 853–857 (2008)PubMedCrossRef S.J. Yoon, H.S. Lee, S.W. Lee, J.E. Yun, S.Y. Kim, E.R. Cho, S.J. Lee, E.J. Jee, H.Y. Lee, J. Park, H.S. Kim, S.H. Jee, The association between adiponectin and diabetes in the Korean population. Metabolism 57, 853–857 (2008)PubMedCrossRef
33.
Zurück zum Zitat Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001)
34.
Zurück zum Zitat S. Inoue, P. Zimmet, I. Caterson, C. Chunming, Y. Ikeda, A.K. Khalid, Y.S. Kim, J. Bassett, The Asia-Pacific perspective: redefining obesity and its treatment. International Obesity Task Force. Western Pacific Region of the World Health Organization (2000) S. Inoue, P. Zimmet, I. Caterson, C. Chunming, Y. Ikeda, A.K. Khalid, Y.S. Kim, J. Bassett, The Asia-Pacific perspective: redefining obesity and its treatment. International Obesity Task Force. Western Pacific Region of the World Health Organization (2000)
Metadaten
Titel
Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population
verfasst von
Jaeseong Jo
Ji Eun Yun
Heeyeon Lee
Heejin Kimm
Sun Ha Jee
Publikationsdatum
01.04.2011
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2011
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-010-9417-2

Weitere Artikel der Ausgabe 2/2011

Endocrine 2/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.